Phaseline

Companies › Delcath Systems

Delcath Systems: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 3; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Melphalan/Hepatic Delivery System (HDS)
Alkylating agent with liver-directed delivery via hepatic perfusion
–Phase 3Metastatic Ocular Melanoma–
Melphalan/HDS
High-dose melphalan delivered directly into the liver via hepatic artery infusion
–Phase 2Refractory Metastatic Colorectal CancerDec 2026
Melphalan/HDS
High-dose melphalan delivered directly to the liver via hepatic artery infusion
MELKPhase 2Metastatic Breast Cancer in the LiverMay 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05022901Melphalan/Hepatic Delivery System (HDS)Phase 3Metastatic Ocular MelanomaOncologyMar 2024
NCT06607458Melphalan/HDSPhase 2Refractory Metastatic Colorectal CancerOncologyDec 2026
NCT06875128Melphalan/HDSPhase 2Metastatic Breast Cancer in the LiverOncologyMay 2029

From the company's SEC filings

Cash and short-term investments of $104m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Complete response letters from FDA

Targets

MELK (1)

Companies with the same targets

OncoTherapy Science

Companies built like this

CG Oncology Hangzhou Converd Abscint NV/SA Beijing Gene Key Life Technology Neuboron Bio-SciTech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.